Go to deals
Healthcare

Cryo-Save N.V. has acquired Salveo Biotechnology SA

Cryo-Save N.V. (Cryo-Save), the largest family stem cell bank in Europe, has acquired Salveo Biotechnology SA, the cord banking activities of Salveo Holding SA (Salveo), for an undisclosed consideration.

Cryo-Save is the leading international stem cell storage brand. It offers collection, analysis, processing and cryogenic preservation of stem cells obtained from the umbilical cord and from umbilical cord blood that can be used in medical therapies later in a child’s lifetime.

Salveo Biotechnology SA is the umbilical cord blood and umbilical cord tissue cryopreservation division of Salveo Holding SA, a Swiss private laboratory based in Geneva, specialized in stem cells cryopreservation, cell culture and regenerative medicine.

Salveo Holding SA is a Swiss private laboratory based in Geneva, specialized in stem cells cryopreservation, cell culture and regenerative medicine. Founded in 2011 and made up of experts in regenerative medicine, the group is also present in Italy, Spain, Portugal and Ukraine and has developed a dynamic and professional commercial network.

Salveo was selected to partner with Cryo-Save, acquiring all assets related to the distribution and commercial activities of Salveo's umbilical cord blood and umbilical cord tissue cryopreservation business. Frédéric Amar, CEO of Salveo, has also joined the board of Cryo-Save as non-Executive Director.

Oaklins' team in the Netherlands identified potential partners, initiated contact and led talks on potential cooperation with a number of parties and advised the buyer in this transaction.

Parties

Talk to the deal team

Robert Boersma

Partner
Amsterdam, Netherlands
Oaklins Netherlands

Maarten Wolleswinkel

Partner
Amsterdam, Netherlands
Oaklins Netherlands

Arjen Kostelijk

Senior Advisor
Amsterdam, Netherlands
Oaklins Netherlands

Related deals

MEDIK Hospital Design Group has been acquired by STERIS
Construction & Engineering Services | Healthcare

MEDIK Hospital Design Group has been acquired by STERIS

The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.

Learn more
bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Healthcare

bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG

Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.

Learn more
SLT has been acquired by Indutrade
Healthcare

SLT has been acquired by Indutrade

SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.

Learn more